Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 422 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Transplantation Recipients Clear all
Completed Phase 2 Interventional Results available

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

NCT05518487
View directory record Official record
Conditions
COVID-19, Kidney Transplant
Interventions
Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 1, 2026, 10:19 PM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 1, 2026, 10:19 PM EDT
Terminated Phase 4 Interventional Results available

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

NCT00983645
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Neoral
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients

NCT00240994
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 1, 2026, 10:19 PM EDT
Not listed Phase 4 Interventional

Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients

NCT00252655
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Rapamune and Prograf
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 1, 2026, 10:19 PM EDT
Active, not recruiting Not applicable Interventional

Curcumin in Kidney Transplant Recipients

NCT03935958
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Curcumin, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 1, 2026, 10:19 PM EDT
Terminated Phase 2 Interventional

Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

NCT00104338
View directory record Official record
Conditions
BK Polyomavirus, Kidney Diseases
Interventions
FK778
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 1, 2026, 10:19 PM EDT
Not listed Phase 2 Interventional

Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function

NCT01837043
View directory record Official record
Conditions
Delayed Graft Function, Kidney Transplant
Interventions
Belatacept, Calcineurin Inhibitor
Drug
Lead sponsor
Nair, Vinay, D.O.
Individual
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 1, 2026, 10:19 PM EDT
Terminated No phase listed Observational

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

NCT02730715
View directory record Official record
Conditions
KIDNEY TRANSPLANTATION
Interventions
Basiliximab, Thymoglobulin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 1, 2026, 10:19 PM EDT
Completed No phase listed Observational

Validation of Gene Expression Markers of Renal Allograft Functional Decline

NCT01782586
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Jacksonville, Florida • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

Sotagliflozin Safety and Tolerability Among Renal Transplant Recipients

NCT05405556
View directory record Official record
Conditions
Kidney Transplant
Interventions
eGFR reporting
Diagnostic Test
Lead sponsor
Martina McGrath, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Not applicable Interventional

Pilot of IMPACT Intervention at the University of New Mexico

NCT04166994
View directory record Official record
Conditions
Kidney Replacement
Interventions
Exercise and diet, No Intervention: Usual Care
Behavioral · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 1, 2026, 10:19 PM EDT
Completed No phase listed Observational

Genomics of Kidney Transplantation

NCT01714440
View directory record Official record
Conditions
KidneyTransplant Recipients, Simultaneous Kidney/Pancreas Recipients, Kidney Transplant Donor
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 2 Interventional Results available

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

NCT02741323
View directory record Official record
Conditions
HIV Infections, Kidney Diseases
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Results available

Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients

NCT00121810
View directory record Official record
Conditions
Kidney Transplantation
Interventions
mycophenolate mofetil [CellCept], Corticosteroids, Calcineurin inhibitors, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
36
States / cities
Bakersfield, California • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 1, 2026, 10:19 PM EDT
Not listed No phase listed Observational

Predicting Mortality in Kidney Transplant Recipients

NCT06531967
View directory record Official record
Conditions
Death
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years to 100 Years
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

NCT00266708
View directory record Official record
Conditions
Renal Transplant Osteodystrophy
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 1, 2026, 10:19 PM EDT
Withdrawn Not applicable Interventional

A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients

NCT03427008
View directory record Official record
Conditions
Medication Adherence, Transplant; Kidney
Interventions
mHealth Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 3 Interventional

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

NCT02610296
View directory record Official record
Conditions
Delayed Graft Function
Interventions
QPI-1002, Placebo
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Not applicable Interventional

L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

NCT00587418
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
L-arginine, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 1, 2026, 10:19 PM EDT
Completed No phase listed Observational

Noninvasive Methods to Monitor Graft Survival in Kidney Transplant Patients

NCT00308802
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney transplantation
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 10:19 PM EDT
Completed No phase listed Observational

CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients

NCT00227045
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2007 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 4 Interventional Results available

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

NCT02152345
View directory record Official record
Conditions
Implant or Graft; Rejection
Interventions
Belatacept, Tacrolimus, Mycophenolate, rATG, Methylprednisolone, Renal transplant
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 1, 2026, 10:19 PM EDT
Completed Phase 2 Interventional

Envarsus XL Immunosuppression Following Liver Transplantation

NCT03828058
View directory record Official record
Conditions
Recipients of Liver Transplant
Interventions
Envarsus XR, Prograf
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 1, 2026, 10:19 PM EDT